C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
Loading...
Date
2015-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Patients with chronic myeloid leukaemia show an excellent
response to treatment with imatinib. However, in some
patients, the disease is resistant to imatinib. This resistance may
be related to the presence of genetic variations on the drug’s
pharmacokinetics and metabolism. We therefore studied three
polymorphisms (C1236T, G2677T and C3435T) in the
human multidrug-resistance gene (MDR1) in 86 patients with
chronic myeloid leukaemia treated with imatinib. Imatinib
resistance was more frequent in patients with TT genotype at
locus 1236 than in those with CT/CC genotypes (p=0.003).
For the other two loci (G2677T and C3435T), resistance was
seen to be higher for TT genotype when compared to GG/GT
and CT/CC but it was not statistically significant (p=0.13 and
p=0.099). In conclusion, determination of C1236T MDR1
genotype may help to predict response to imatinib therapy in
patients with chronic myeloid leukaemia.
Natl Med J India 2015;28:272–5
Description
Keywords
Citation
Chhikara Unita, Sazawal Sudha, Mishra Pravas, Chaubey Rekha, Mahapatra Manoranjan, Saxena Renu. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia. National Medical Journal of India. 2015 Nov-Dec; 28(6):272-275.